2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111308
    RTI-118 847554-50-1 99.90%
    RTI-118 is a novel small-molecule neuropeptide S receptor (NPSR) antagonist. RTI-118 can relieve agent addiction including selectively decrease self-administration.
    RTI-118
  • HY-112269
    Glutaminyl Cyclase Inhibitor 1 2110449-60-8 99.61%
    Glutaminyl Cyclase Inhibitor 1 is a glutaminyl cyclase inhibitor with an IC50 of 0.5 μM.
    Glutaminyl Cyclase Inhibitor 1
  • HY-113739
    Desmethylcitalopram hydrochloride 97743-99-2 99.87%
    Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC50s of 39.5 and 53.5 μM.
    Desmethylcitalopram hydrochloride
  • HY-113845
    (+)-Intermedine 10285-06-0 99.0%
    (+)-Intermedine, a pyrrolizidine alkaloid (PA), exhibits significant cytotoxicity in neural progenitor cells (NPCs).
    (+)-Intermedine
  • HY-114871
    SL651498 205881-86-3 98.2%
    SL651498 is a full agonist of α2 and α3 GABAA receptors, and a partial agonist of α1 and α5 GABAA receptors. SL651498 shows anxiolytic and anticonvulsant activities.
    SL651498
  • HY-114903
    (E/Z)-BIO-acetoxime 740841-15-0 99.9%
    (E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC50 of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC50=2.4, 4.3, 63 μM).
    (E/Z)-BIO-acetoxime
  • HY-114926
    KT185 1472640-86-0 ≥98.0%
    KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC50 0.21 nM in Neuro2A cells.
    KT185
  • HY-114978
    VU0424465 1428630-85-6 99.84%
    VU0424465 is a potent and partial PAM (positive allosteric modulator)-agonist for mGlu5 mediated iCa2+ mobilization. VU0424465 exhibits high affinity at MPEP allosteric binding site, with a Ki value of 11.8 nM. VU0424465 is also a agonist for pERK1/2 in cortical neurons.
    VU0424465
  • HY-115483
    VU0477573 1946021-40-4
    VU0477573 is a brain-penetrant partial negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5). VU0477573 exhibits neuroprotective and anxiolytic effects. VU0477573 can be used for the research of neurological disease, such as Parkinson disease.
    VU0477573
  • HY-115597
    BTT-266 2413939-89-4 98.90%
    BTT-266 is an antagonist forcalcium channel, through suppression of the CaVα1-AID-CaVβ3 interaction, with a Ki of 1.4 μM. BTT-266 modulates the activation of voltage-dependent CaV2.2. BTT-266 exhibits analgesic efficacy against neuropathic pain in rats model.
    BTT-266
  • HY-115741
    3BrB-PP1 956025-99-3 99.0%
    3BrB-PP1 is an ATP-competitive analog. 3BrB-PP1 can specifically inhibit the activity of protein kinase with mutations in the ATP-binding pocket (mutation of Thr97 within Sty1’s ATP-binding pocket).
    3BrB-PP1
  • HY-116016
    Etilevodopa 37178-37-3
    Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine.
    Etilevodopa
  • HY-116018
    FKGK11 1071000-98-0 99.9%
    FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis.
    FKGK11
  • HY-116082
    CP 226269 220941-93-5 99.65%
    CP 226269 is a potent dopamine D4 receptor agonist that induces calcium flux with EC50 of 32 nM. CP 226269 stimulates phospholipid methylation (PLM) in SK-N-MC neuroblastoma cells with an EC50 of 2.9 nM. CP 226269 can be used in the research of schizophrenia and other related diseases.
    CP 226269
  • HY-116100
    (E/Z)-HA155 1229652-22-5 99.58%
    (E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor. (E/Z)-HA155 can be used for researching cancer, fibrotic diseases, inflammation, pain and angiogenesis.
    (E/Z)-HA155
  • HY-116181
    YQA14 1221408-42-9 98.62%
    YQA14 is a high affinity dopamine D3 receptor antagonist. YQA14 is anti-opioid addiction agent. YQA14 inhibits Morphine/Cocaine-induced conditioned place preference (CPP) in animals.
    YQA14
  • HY-116535
    D-threo-PPMP hydrochloride 139889-65-9 98.0%
    D-threo-PPMP hydrochloride is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP hydrochloride can block karyokinesis and reduce cyst production.
    D-threo-PPMP hydrochloride
  • HY-116561
    Adamantylmethamphetamine hydrochloride 19835-42-8 ≥98.0%
    Adamantylmethamphetamine hydrochloride is a psychotic compound. Adamantylmethamphetamine hydrochloride has effects on hexobarbital sleeping time, spontaneous motor activity, and the potentiation of metrazole and antifatigue activity.
    Adamantylmethamphetamine hydrochloride
  • HY-116625
    PF-04628935 1383719-97-8 99.1%
    PF-04628935 (compound 10n) is a potent ghrelin receptor inverse agonist, with an IC50 of 4.6 nM. PF-04628935 exhibits oral bioavailability of 43% in rats and shows reasonable penetration into the brain. PF-04628935 can be used for stress and anxiety research.
    PF-04628935
  • HY-116746
    Clopimozide 53179-12-7 99.63%
    Clopimozide is an orally active antischizophrenic agent that inhibits [3H]nitrendipine binding with IC50 value of 17 nM. Clopimozide is a calcium channel antagonist. Clopimozide can be used for the research of negative and positive schizophrenic symptoms.
    Clopimozide
Cat. No. Product Name / Synonyms Application Reactivity